Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide

Active targeting and specific drug delivery to parenchymal liver cells is a promising strategy to treat various liver disorders. Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Witzigmann, Dominik (Verfasst von) , Uhl, Philipp (Verfasst von) , Kaufman, Christina (Verfasst von) , Schöneweis, Katrin (Verfasst von) , Ni, Yi (Verfasst von) , Mier, Walter (Verfasst von) , Urban, Stephan (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 23 July 2019
In: eLife
Year: 2019, Jahrgang: 8
ISSN:2050-084X
DOI:10.7554/eLife.42276
Online-Zugang:Verlag, Volltext: https://doi.org/10.7554/eLife.42276
Verlag: https://elifesciences.org/articles/42276
Volltext
Verfasserangaben:Dominik Witzigmann, Philipp Uhl, Sandro Sieber, Christina Kaufman, Tomaz Einfalt, Katrin Schöneweis, Philip Grossen, Jonas Buck, Yi Ni, Susanne H. Schenk, Janine Hussner, Henriette E. Meyer zu Schwabedissen, Gabriela Québatte, Walter Mier, Stephan Urban, Jörg Huwyler
Beschreibung
Zusammenfassung:Active targeting and specific drug delivery to parenchymal liver cells is a promising strategy to treat various liver disorders. Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-taurocholate cotransporting polypeptide (NTCP; SLC10A1) on the sinusoidal membrane of hepatocytes. Physicochemical properties of targeted nanoparticles were optimized and NTCP-specific, ligand-dependent binding and internalization was confirmed in vitro. The pharmacokinetics and targeting capacity of selected lead formulations was investigated in vivo using the emerging zebrafish screening model. Liposomal nanoparticles modified with 0.25 mol% of a short myristoylated HBV derived peptide, that is Myr-HBVpreS2-31, showed an optimal balance between systemic circulation, avoidance of blood clearance, and targeting capacity. Pronounced liver enrichment, active NTCP-mediated targeting of hepatocytes and efficient cellular internalization were confirmed in mice by 111In gamma scintigraphy and fluorescence microscopy demonstrating the potential use of our hepatotropic, ligand-modified nanoparticles.
Beschreibung:Gesehen am 06.11.2019
Beschreibung:Online Resource
ISSN:2050-084X
DOI:10.7554/eLife.42276